|The Expanding Role of JAK Inhibitors in MF|
Ruben Mesa, MD
|Release Date: June 16, 2021|
Expiration Date: June 16, 2022
Join Dr. Mesa as he discusses new opportunities for JAK inhibitors in myelofibrosis (MF). Topics will include the ruxolitinib phase 3 COMFORT I and II trials, management of early-onset treatment-associated cytopenia, and outcomes associated with fedratinib in the JAKARTA and JAKARTA-2 trialsProvided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation.
|Begin, Earn CreditView Only, No Credit|